+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Farxiga"

From
Empagliflozin, Dapagliflozin and Canagliflozin Market Report 2024 - Product Thumbnail Image

Empagliflozin, Dapagliflozin and Canagliflozin Market Report 2024

  • Report
  • September 2024
  • 175 Pages
  • Global
From
Diabetes Care Drugs Market - Forecasts from 2022 to 2027 - Product Thumbnail Image

Diabetes Care Drugs Market - Forecasts from 2022 to 2027

  • Report
  • October 2022
  • 138 Pages
  • Global
From
From
Sodium-glucose transporter 2 inhibitors - Pipeline Insight, 2024 - Product Thumbnail Image

Sodium-glucose transporter 2 inhibitors - Pipeline Insight, 2024

  • Drug Pipelines
  • January 2024
  • 60 Pages
  • Global
From
FARXIGA Market Size, Forecast, and Emerging Insight - 2032 - Product Thumbnail Image

FARXIGA Market Size, Forecast, and Emerging Insight - 2032

  • Report
  • April 2024
  • 30 Pages
  • Global
From
From
From
From
From
From
From
From
From
From
From
From
Loading Indicator

Farxiga is a medication used to treat type 2 diabetes, a condition in which the body does not produce enough insulin or does not use insulin properly. It belongs to a class of drugs known as sodium-glucose cotransporter-2 (SGLT2) inhibitors, which work by blocking the reabsorption of glucose in the kidneys, allowing it to be excreted in the urine. Farxiga is also used to reduce the risk of cardiovascular death in adults with type 2 diabetes and established cardiovascular disease. Farxiga is part of the Endocrine and Metabolic Disorders Drugs market, which includes medications used to treat conditions such as diabetes, obesity, and thyroid disorders. These drugs are used to help regulate hormones and metabolism, and can be taken orally or injected. Companies in the Farxiga market include AstraZeneca, Boehringer Ingelheim, Eli Lilly, Merck, Novo Nordisk, and Sanofi. Show Less Read more